Studies show that the nasal spray from a Viennese pharmaceutical company protects against corona infection. Since then the Marinomed share has been booming.
The “Coldamaris pro” nasal spray is effective against colds, costs 10 euros in the pharmacy and has been on the market since 2008. But the spray from the Viennese biotech company Marinomed is likely to have one more property: it should offer “significant protection” against corona infection. This is proven by a new clinical study on hospital staff who cared for corona patients.
As soon as the study became known, a run on shares in the pharmaceutical company began, the price jumped 20 percent to up to 147 euros. The spray with Carragelose, an active ingredient in red algae, “keeps the virus from infecting other cells,” says another study by the University of Erlangen. The “duration and severity” of symptoms would be reduced. Even the German “Society for Hospital Hygiene” recommends the spray.
The founding couple Eva and Andreas Grassauer are now planning the next trick: lozenges that work in the throat against the corona virus.
